Cannabinoids have therapeutic potential in oxidative stress-related acute or chronic neurodegenerative disorders from stroke, multiple sclerosis and traumatic brain injury to Alzheimer`s and Parkinson`s diseases, according to a new study.
The study, conducted by researchers at the National Institute of Health (NIH) and Rutgers New Jersey Medical School, is being published in the journal Antioxidants & Redox Signaling, and has been e-published ahead of print by NIH’s PubMed.gov.
According to the study’s abstract:
Redox imbalance may lead to overproduction of reactive oxygen and nitrogen species (ROS/RNS) and subsequent oxidative tissue damage which is a critical event in the course of neurodegenerative diseases. It is still not fully elucidated, however, whether oxidative stress is the primary trigger or a consequence in process of neurodegeneration. Recent Advances: Increasing evidence suggests that oxidative stress is involved in the propagation of neuronal injury and consequent inflammatory response, which in concert promote development of pathological alterations characteristic of most common neurodegenerative diseases. Critical Issue: Accumulating recent evidence also suggests that there is an important interplay between the lipid endocannabinoid system (ECS; comprising of the main cannabinoid 1 and 2 receptors (CB1 and CB2), endocannabinoids and their synthetic and metabolizing enzymes) and various key inflammatory and redox-dependent processes.
Researchers state that; “Targeting the ECS [endocannabinoid system, done naturally by cannabis and cannabinoids] in order to modulate redox state-dependent cell death, and to decrease consequent or preceding inflammatory response holds therapeutic potential in multitude of oxidative stress-related acute or chronic neurodegenerative disorders from stroke and traumatic brain injury to Alzheimer`s and Parkinson`s diseases, and multiple sclerosis, just to name a few”.